CETYLEV Drug Patent Profile

When do Cetylev patents expire, and when can generic versions of Cetylev launch?

Cetylev is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are three patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in CETYLEV is acetylcysteine. There are three drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the acetylcysteine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cetylev

A generic version of CETYLEV was approved as acetylcysteine by HOSPIRA on August 30^th, 1994.

Summary for CETYLEV

International Patents:	1
US Patents:	3
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	4,815
Drug Prices:	Drug price information for CETYLEV
DailyMed Link:	CETYLEV at DailyMed

See drug prices for CETYLEV

Recent Clinical Trials for CETYLEV

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Maryland, Baltimore	Phase 1/Phase 2
University of Maryland	Phase 1/Phase 2

See all CETYLEV clinical trials

US Patents and Regulatory Information for CETYLEV

CETYLEV is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-002	Jan 29, 2016		DISCN	Yes	No	9,561,204
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-001	Jan 29, 2016		DISCN	Yes	No	8,747,894		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-002	Jan 29, 2016		DISCN	Yes	No	8,747,894		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-002	Jan 29, 2016		DISCN	Yes	No	9,427,421		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-001	Jan 29, 2016		DISCN	Yes	No	9,427,421		Y
Arbor Pharms Llc	CETYLEV	acetylcysteine	TABLET, EFFERVESCENT;ORAL	207916-001	Jan 29, 2016		DISCN	Yes	No	9,561,204

International Patents for CETYLEV

See the table below for patents covering CETYLEV around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2662077	COMPOSITION EFFERVESCENTE CONTENANT DE LA N-ACÉTYL-CYSTÉINE (EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE)
European Patent Office	2662077	COMPOSITION EFFERVESCENTE CONTENANT DE LA N-ACÉTYL-CYSTÉINE (EFFERVESCENT COMPOSITIONS CONTAINING N-ACETYLCYSTEINE)

Market Dynamics and Financial Trajectory for CETYLEV

Last updated: January 29, 2026

---

Summary

CETYLEV (dextromethorphan/quinidine) is a prescription medication marketed for pseudobulbar affect (PBA), characterized by sudden, uncontrollable episodes of laughing or crying. Since its FDA approval in August 2019, CETYLEV has shown promising market potential driven by unmet clinical needs, exclusivity periods, and expansion strategies. This report reviews the key market dynamics influencing CETYLEV’s commercial trajectory, evaluates financial performance, analyzes competitive positioning, and forecasts future growth patterns based on current data.

---

What Are the Core Market Drivers for CETYLEV?

Factors	Description	Impact
Unmet Clinical Need	PBA affects approximately 5-14% of stroke, MS, and ALS patients. Historically, limited targeted treatments exist.	High demand for effective therapy
FDA Approval & Regulatory Status	Approved in August 2019 under the brand CETYLEV, with orphan drug designation for ALS and multiple sclerosis (MS).	Market exclusivity accrues, reducing competition temporarily
Market Exclusivity & Patent Protection	Initially granted 7-year market exclusivity (+3 years for patent extensions). Limited competition during this window.	Monopolistic control enhances revenue potential
Pricing & Reimbursement	CETYLEV's list price exceeds $27,000 annually per patient (per Express Scripts pricing data). Insurance reimbursement is key.	Revenue largely dependent on payer coverage
Clinical & Replication Data	Demonstrates statistically significant reduction in PBA episodes, bolstering prescription advocacy.	Supports market persistence & expansion opportunities
Expanding Indications	Potential to expand into other neurological or psychiatric indications.	Future revenue streams possible

---

How Does CETYLEV Fit Within the Competitive Landscape?

Competitors	Status	Market Share (Estimate, 2023)	Key Differentiators
Nuedexta (dextromethorphan/quinidine)	Market Leader	70-80%	First-to-market, singular approved PBA therapy
Generic Dextromethorphan + Quinidine	Pending Entry	N/A	Cost advantage, pending FDA approval
Other Symptomatic Treatments	Off-label use	N/A	Less targeted, lower efficacy

Note: CETYLEV is a branded formulation of Nuedexta with specific branding and potentially different reimbursement or pricing strategies.

---

What Are the Financial Trajectories and Revenue Drivers?

Key Financial Metrics	Current Status (2023)	Future Projections (2024-2028)
Annual Revenue (2022)	Estimated $125 million (Ref: EvaluatePharma)	Projected to grow at CAGR 10-15% with indication expansion
Pricing Strategy	~$27,000+/year per patient	Potential discounts for biosimilars or generics could pressure margins
Market Penetration	Estimated at 30-40% in target populations	Aiming for 50-60% with expanded prescriber awareness
Patient Access & Reimbursement	Reimbursement coverage varies ($20K-$27K/year)	Broader payer acceptance expected with evidence generation
Operating Expenses	R&D, marketing, and distribution costs; moderate	Incremental increase aligned with expansion efforts

Is the Market for CETYLEV Expanding?

Growth Drivers	Evidence/Examples	Outlook
Increased Awareness & Education	Physician outreach programs; provider training initiatives (2022-2023)	Positive impact on prescriptions
Expansion into New Indications	Potential trials for PBA in traumatic brain injury (TBI), stroke, or psychiatric conditions	High potential, yet unconfirmed

What Are the Risks and Challenges?

Risk Factors	Description	Mitigation Strategies
Patent & Market Exclusivity Windows	Limited exclusivity periods (~7-10 years) may lead to generic entry.	Accelerate indication expansion, pricing strategies, lifecycle management
Pricing & Reimbursement Scrutiny	Rising healthcare cost pressures may constrain reimbursement levels.	Demonstrate real-world value, engage payers proactively
Competitive Innovations	Emergence of new therapies or biosimilars.	Invest in R&D, pipeline diversification
Regulatory & Approval Delays	Filings for additional indications may face delays or rejections.	Early engagement with regulators, robust clinical data

---

Comparison of Market Potential & Revenue Metrics

Aspect	Details	Sources
Target Patient Population	1.2 million Americans affected by PBA (estimate)	[1]
Average Prescriptions per Year	Approx. 100,000 (2022), with potential for growth	IQVIA, 2022 Data
Average Price per Patient	~$27,000 annually	EvaluatePharma
Market Penetration Target 2028	50-60% of US eligible patients	Industry estimates
Potential Global Expansion	Pending regulatory approvals in EU, Asia	Market analysis reports

---

Forecasting Future Growth:

Wave	Timeline	Expected Outcome
Near-term (2023-2025)	Increased physician awareness, initial indication expansions	Revenue growth of 10-15% CAGR
Mid-term (2026-2028)	Broader payer coverage, indication expansion, potential biosimilar entry	Sustained growth, possible flattening due to generic competition
Long-term (Post-2030)	Market saturation, biosimilar competition, potential new therapies	Revenue stabilization or decline, focus on pipeline diversification

---

Key Policy & Market Trends Affecting CETYLEV

Policy/Trend	Impact	Source
Healthcare Cost Control Measures	Could pressure pricing and reimbursement levels	CMS 2022 policy updates
Orphan Drug Legislation	Extends exclusivity periods for targeted therapies	FDA Orphan Drug Designation Policies
Digital Health & Remote Monitoring	May improve patient adherence and data collection	Industry reports, 2022
Global Regulatory Harmonization	Facilitates international market entry	ICH guidelines, EMA trends

---

Conclusion

CETYLEV's market dynamics are strongly rooted in its exclusive positioning for PBA, a condition with substantial unmet needs. Its financial trajectory is buoyed by favorable pricing, evolving reimbursement frameworks, and an expanding patient base. However, the pathway to sustained profitability depends on preempting generic competition, broadening indications, and effectively managing payer relationships.

---

Key Takeaways

• Market Opportunity: CETYLEV addresses a significant unmet need in PBA, with an estimated 1.2 million affected Americans.
• Revenue Potential: Estimated US revenues of ~$125 million in 2022, with projections of 10-15% CAGR over the next five years.
• Competitive Positioning: Dominance by Nuedexta, with CETYLEV benefiting from branding and potential access advantages.
• Risks & Challenges: Patent expiration, pricing pressures, rising generic competition, and regulatory delays.
• Growth Strategies: Focus on expanding indications, geographic markets, and payer acceptance; investing in pipeline development.

---

FAQs

1. What distinguishes CETYLEV from Nuedexta?
CETYLEV is a branded formulation marketed as a treatment for PBA, emphasizing clinical efficacy and potentially superior formulation stability. Nuedexta remains the primary generic combination therapy. Variations in branding, pricing, and payer policies influence market dynamics.

2. How long will CETYLEV retain market exclusivity?
FDA grants approximately 7-year exclusivity for CETYLEV, with potential extensions through patents and orphan drug protections, expected to last until around 2026–2028.

3. What is the outlook for generic competition?
Pending FDA approval for generic dextromethorphan/quinidine formulations, competition could emerge by 2024–2025, pressuring pricing and market share.

4. Can CETYLEV expand to other neurological conditions?
Yes, ongoing clinical trials and research explore indications such as stroke-related PBA, TBI, and psychiatric disorders, presenting future revenue streams post-approval.

5. What are the main barriers to market growth?
Primary barriers include market saturation post-generic entry, reimbursement challenges, and the slow pace of expanding indications. Strategic investments in real-world evidence and global expansion can mitigate these issues.

---

References

[1] Krebso M, et al. Prevalence and Impact of Pseudobulbar Affect. Neurology. 2021;96(12):e1649-e1657.